Literature DB >> 19565609

Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.

Ranjit Akolekar1, Davide Casagrandi, Panagiotis Livanos, Amos Tetteh, Kypros H Nicolaides.   

Abstract

OBJECTIVE: To investigate whether in pregnancies that subsequently develop preeclampsia (PE), the maternal plasma concentration of the inflammatory factor pentraxin 3 (PTX3) at 11-13 weeks of gestation is increased and whether such a possible increase is associated with uterine artery pulsatility index (PI).
METHODS: The concentration of plasma PTX3 at 11-13 weeks was measured in a case-control study from 120 pregnancies that developed PE, including 27 who required delivery before 34 weeks (early PE), 87 cases of gestational hypertension (GH) and 207 normal controls. The median PTX3 multiple of the median (MoM) in the control and hypertensive groups were compared. Regression analysis was used to determine the significance of the association between plasma PTX3 and uterine artery PI.
RESULTS: Plasma PTX3 was significantly higher in the early PE group (1.44 MoM; p < 0.0083) but not in late PE (1.11 MoM) or GH (1.10 MoM) compared to the controls (0.97 MoM). There was no significant association between plasma PTX3 levels and uterine artery PI in either the PE group (p = 0.693) or in the controls (p = 0.209).
CONCLUSION: Increase in maternal plasma PTX3 in pregnancies that subsequently develop early PE is evident from 11-13 weeks but the underlying mechanism for such an increase remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565609     DOI: 10.1002/pd.2311

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

Review 1.  Pre-eclampsia: Molecular events to biomarkers.

Authors:  Kavita Sahai; Seema Saraswathy; Tribhuvan Pal Yadav; Devendra Arora; Manu Krishnan
Journal:  Med J Armed Forces India       Date:  2016-11-17

Review 2.  Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  World J Nephrol       Date:  2014-11-06

3.  Pentraxin 3 values during normal pregnancy.

Authors:  Anders Larsson; Maria Palm; Johanna Helmersson; Ove Axelsson
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

4.  Pentraxin 3 in maternal circulation: an association with preterm labor and preterm PROM, but not with intra-amniotic infection/inflammation.

Authors:  Laura Cruciani; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Shali Mazaki-Tovi; Zhong Dong; Sun Kwon Kim; Giovanna Ogge; Lami Yeo; Pooja Mittal; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-10

Review 5.  Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?

Authors:  Sinuhe Hahn; Olav Lapaire; Nandor Gabor Than
Journal:  Expert Rev Mol Diagn       Date:  2015-03-16       Impact factor: 5.225

Review 6.  Cardiovascular Complications of Pregnancy.

Authors:  Maria Carolina Gongora; Nanette K Wenger
Journal:  Int J Mol Sci       Date:  2015-10-09       Impact factor: 5.923

7.  Early second trimester maternal serum markers in the prediction of gestational diabetes mellitus.

Authors:  Baihui Zhao; Xiujun Han; Qing Meng; Qiong Luo
Journal:  J Diabetes Investig       Date:  2018-01-28       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.